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Abstract Recombinant vaccinia virus vectors were used to coex- 
press each of the candidate prohormone convertases PC1, PC2, 
furin, PACFA and PC5 with rat prosomatostatin (rProSOM) in 
the constitutive secreting cell line LoVo and in the endocrine 
corticotroph cell line AtT-20, which exhibits regulated secretion. 
Mammalian ProSOM is cleaved at a dibasic Arg-Lysi site to 
produce somatostatin-14 (S-14) and at a monobasic Gln-Argi 
site to yield somatostatin-28 (S-28). The analysis of processed 
products by gel-permeation high performance liquid chromatog- 
raphy shows that in LoVo cells PCI, furin and PACE4 generate 
S-14, S-28 and a mixture of S-14 and S-28, respectively, while 
PC2 is unable to process ProSOM in these constitutive cells. In 
contrast, PC2 can generate S-14 in AtT-20 cells. The convertase 
PC5 is unable to process ProSOM in either cell line. These data 
suggest hat PC2, PC1 and PACE4 are candidate S-14 conver- 
tases, while PACE4 and furin are candidate S-28 convertases. 
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I. Introduction 
Post-translational proteolysis is a common mechanism re- 
quired for the synthesis of biologically active peptides and pro- 
teins in eukaryotes [1,2]. Such processing occurs at either single 
or pairs of basic amino acids [3], Genetic evidence suggests that 
pairs of basic amino acids are necessary for prohormone proc- 
essing, since mutations in one of the basic residues present in 
the cleavage site of proinsulin, for example, result in secretion 
of the precursor ather than the mature protein [4]. However, 
not all single or pairs of basic residues are signals for intracel- 
lular cleavage. There is now ample evidence that the presence 
of basic amino acids, although necessary, is not sufficient o 
direct recognition by the physiologically relevant endopro- 
teases, and that other secondary structure determinants favor 
the processivity of a given site within a precursor [5]. 
Six processing enzymes, generally referred to as the precur- 
sor convertases (PCs), have been identified in mammalian spe- 
cies. These Ca2+-dependent serine proteinases belonging to the 
subtilisin/kexin family are called PC1/3, PC2, furin, PC4, 
PACE4 and PC5/6 (for reviews see [2,3,6]). In general, it was 
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found that the catalytic segment of each convertase represents 
the sequence that is most conserved between the members of 
the family, with PC2 showing the least sequence similarity. Of 
all these convertases, only furin is ubiquitously expressed, while 
PACE4 and PC5 exhibit a widespread tissue distribution in 
both regulated and constitutive cells [7]. In contrast, PC1 and 
PC2 seem to be predominantly expressed in endocrine and 
neural cells, and PC4 is exclusively synthesized within germ 
cells of the testis [7]. 
The cleavage preference of the convertases has been studied 
by their coexpression with a number of pro-proteins and pro- 
hormones. From these studies it became apparent hat each 
convertase exhibits aspecificity of cleavage post single or pairs 
of basic residues (for reviews see [2,811). In addition, the data 
showed that the intracellular cleavage kinetics of specific bonds 
in precursors are determined by a multiplicity of factors, includ- 
ing convertase activation, substrate specificity and intracellular 
environment [9]. Coexpression studies with vaccinia virus re- 
combinants have proven useful to determine if a given precur- 
sor substrate can be cleaved intracellularly by a candidate con- 
vertase ither in constitutive or regulated cells [10-13]. 
In mammals a unique gene encodes prosomatostatin which 
contains a single Argl and an ArgLysi cleavage site [14]. Proc- 
essing occurs at the COOH-terminal segment of the molecule 
and generates two bioactive forms: somatostatin-14 (S-14) by 
cleavage post ArgLysi and somatostatin-28 (S-28) following a 
GlnArgi cleavage. Cleavage at the ArgLysl site yields S-14 and 
an 8 kDa peptide [15 17], whereas endoproteolysis at the mon- 
obasic Argl site generates S-28 and a 7 kDa peptide [18,19]. 
In a previous work we have shown that PC 1 is able to process 
ProSOM in the constitutive COS-7 cells, whereas PC2 was 
unable to do so [20]. In a subsequent s udy it was shown that 
stable transfectants of mPC2 together with rProSOM in the 
regulated cells GH4C1 or GH3 produce S-14 (Galanopoulou, 
A.S., Seidah, N.G. and Patel, Y.C. 1995, submitted). In the 
present work, we exploited the vaccinia virus expression system 
to compare the processing of rat ProSOM by each of the con- 
vertases PC1, PC2, furin, PACE4 and PC5 in either AtT-20 or 
LoVo cells, as prototypes of regulated and constitutive cells, 
respectively. Although LoVo cells endogenously express 
PACE4 and furin [7], the latter convertase is not functional [21]. 
In order to identify the enzyme(s) involved in the generation of 
S-14 and/or S-28, the resultant peptides present in cellular ex- 
tracts and culture media were identified by a C-terminally di- 
rected radioimmunoassay following fractionation by gel- 
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permeation high performance liquid chromatography (GP- 
HPLC). The data demonstrate that S-14 is generated by the 
action of either PC1 or PC2 in AtT-20 cells and by only PC1 
in LoVo cells, whereas PACE4 generates both S-28 and S-14 
in both cell types. Moreover, in either cells furin processes 
ProSOM into S-28, and PC5 is relatively inactive. 
2. Materials and methods 
LoVo AIT-20 
A 
The coinfections of either AtT-20 or LoVo cells (50×106 cells) with 
a vaccinia virus recombinant of each convertase VV:mPCI, 
VV:mPC2, VV:hfurin, VV:hPACE4 and VV:mPC5 with 
VV:rProSOM were performed overnight at a multiplicity of infection 
of 1 plaque forming unit/cell, as previously reported [9,11,12]. Follow- 
ing an overnight infection, the cells were washed and then further 
incubated in a serum free-medium for 4 h, as reported [12]. The cells 
were then extracted with 0.5 vol. of glacial acetic acid, and sonicated 
four times for 30 s, and the supernatant following centrifugation was 
passed through an ODS-silica cartridge (Sep-pak C~8; Waters Inc.) 
which was equilibrated with 0.1% trifluroacetic acid (TFA). Similarly, 
the media were diluted with 0.5 vol. of glacial acetic acid and then 
loaded onto the ODS cartridge. The adsorbed peptides were eluted with 
80% acetonitrile in 0.1% TFA. Peptides from both the cell extracts and 
the culture media were fractionated by GP-HPLC using two tandem 
Protein-Pak 60 columns (Waters Inc.), eluted with 40% acetonitrile, 
0.1% TFA. Fractions of 0.5 ml were collected and then analyzed using 
a C-terminally directed RIA recognizing S-14 [19]. The percentages of
the products were calculated following integration of the areas of the 
S14-1ike immunoreactivities and dividing the area occupied by either 
S-14 or S-28 by the total area. 
3. Results and discussion 
We have previously shown that S-28 and S-14 are generated 
in the constitutive and regulated pathways, respectively [22]. In 
an effort to identify the candidate subtilisin/kexin-like en- 
zyme(s) involved in vivo in the generation of these peptides, an 
RIA directed against S-14 was performed on GP-HPLC frac- 
tions obtained from infected cells and conditioned medium. 
Two kinds of cells were used: the constitutive LoVo cells which 
are devoid of furin activity [21] but not of PACE4 [7], and the 
regulated AtT-20 cells which possess both regulated and consti- 
tutive secretory pathways. 
The control coinfection of Lovo cells with VV: rProSOM and 
VV:mpro-opiomelanocortin (mPOMC; CTL) resulted in no 
S-14 production and only a very limited cleavage of ProSOM 
into S-28 (12%) which was secreted into the medium (Fig. 1A). 
It is interesting to note that media collected for 4 h contained 
more ProSOM than the cell extract, in accordance with the 
constitutive character of these cells. This cleavage may be af- 
forded by the endogenous convertase PACE4 which is detecta- 
ble in LoVo cells [7]. A similar control experiment performed 
in AtT-20 cells, although revealing an intracellular 28% proc- 
essing into S-14 and 10% into S-28, also showed that only 
ProSOM is released under basal conditions (Fig. 1B). This 
pattern differs somewhat from the one we recently reported 
[22], in which the presence of S-28 and S-14 were detected in 
the culture medium under basal conditions. The differences 
may probably be related to our analysis in this study of a 4 h 
basal secretion medium, as compared to a 16 h secretion me- 
dium analyzed previously [22]. The intracellular processing pat- 
tern observed in ART-20 (Fig. I B) probably reflects the presence 
of endogenous convertases, with PC1 being the major one and 
PC2/PACE4 being minor [7]. Above these endogenous activi- 
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Fig. 1. GP-HPLC analysis of ProSOM processing in LoVo 
(A,C,E,G,I,K) and AtT20 (B,D,F,H,J,L) cells. The cells were coin- 
fected with VV:rProSOM and either VV:POMC (CTL) or each of 
VV: mPC1, VV:mPC2, VV: hfurin, VV : hPACE4 and VV: mPC5. The 
media represent the 4 h collection following overnight growth. The 
chromatograms presented correspond to the elution pattern of the 
media and the cell extract equivalent to 12.5x106 cells which were 
applied to two tandem gel-permeation HPLC columns (Protein-Pak 60; 
Waters). Each fraction (0.5 ml) was lyophylized and the S-14-1ike im- 
munoreactivity was estimated by a C-terminally directed radioimmu- 
noassay and expressed as pg/total fraction. The arrows indicate the 
elution positions of pro-somatostatin (ProSOM), somatostatin-28 (S-
28) and somatostatin-14 (S-14). 
ties, coinfection of VV: rProSOM with each VV:PC is expected 
to enhance, in some cases, the extent of processing of ProSOM. 
From the results presented in Fig. 1 and the calculations of 
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Fig. 2. Proposed processing scheme of the 92 amino acid rat rProSOM 
emphasizing the convertases involved in the production of either S-28 
(single R ~ cleavage) or S-14 (RKI cleavage) inthe constitutive pathway 
and S-14 in the regulated pathway. It should be noted that within the 
constitutive pathway of regulated cells such as AtT20, the production 
of S-28 occurs, but to some extent the latter is further processed to S-14. 
the levels of each product with respect to the total somatostatin- 
like immunoreactivity (IR-SOM), we were able to deduce the 
convertases which are likely to be responsible for the cleavage 
of ProSOM into S-14 and S-28 in either LoVo (Fig. 
1A,C,E,G,I,K) or AtT-20 (Fig. 1B,D,F,H,J,L) cells. Accord- 
ingly, in LoVo cells S-14 is best produced by PACE4 (38% of 
media IR-SOM; Fig. lI) and to a lesser extent by PC1 (19% of 
media IR-SOM; Fig. 1C). In AtT-20 cells, however, PC2 is the 
best S-14 convertase (54% of cellular IR-SOM; Fig. 1F), fol- 
lowed by furin (40% of cellular IR-SOM; Fig. 1H) and PACE4 
(38% of cellular IR-SOM; Fig. 1J). We note that furin mostly 
generated S-28 in LoVo cells (Fig. 1G) but significantly stimu- 
lated the production of both S-28 and S-14 in AtT-20 cells (Fig. 
1H). This may suggest that in AtT-20 cells this Golgi-localized 
enzyme converts ProSOM into S-28 which is then further proc- 
essed into S-14 by the PC1 endogenous toAtT-20 but not LoVo 
cells [7]. As previously observed [20], we note that in constitu- 
tive cells, PC2 is unable to process ProSOM into S-14 or S-28 
(Fig. 1E). The present data and those reported earlier [20] allow 
us to conclude that PC1 could produce S-14 in constitutive cells 
but that PC2 needs a regulated secretory pathway to be active. 
We also note that PC5 is not able to produce significant 
amounts of $14 in either cell (Fig. 1K,L). This is not due to low 
expression levels of inactive PC5 since Northern blot analyses 
ofVV :mPC5 infected cells demonstrated a large increase in the 
mRNA level of this enzyme (not shown), and a similar coex- 
pression of this convertase with the neuroendocrine protein 
pro7B2 demonstrated that PC5 can process this precursor to 
7B2 [23]. The results presented in Fig. 1 also suggest that both 
furin and PACE4 are as efficient in processing ProSOM into 
S-28 in either LoVo (27% of media IR-SOM; Fig. 1G,I) or 
AtT-20 (19% of cellular IR-SOM; Fig. 1H,J) cells. We note 
that, especially in the case of AtT-20 cells, a significant shoulder 
of S-I 4 immunoreactivity s detected, eluting just after the pre- 
cursor. The amount of this material, which must contain the 
C-terminal epitope, is increased by coexpression of the conver- 
tases, especially furin and PACE4. This N-terminally truncated 
intermediate, which has been previously observed [20], proba- 
bly results from the cleavage of the N-terminal segment of 
proSOM at Lys t° in order to produce antrin. Finally, it is also 
apparent that neither PC1, PC2 or PC5 can cleave ProSOM 
into S-28 (Fig. 1C,D,E,F,K,L). 
Our results are in good agreement with recent immunocyto- 
chemical colocalization studies in rat and mouse pancreatic 
islets showing that only PC2, but not PC1, colocalizes with 
somatostatin [24]. The analysis of the different forms of im- 
munoreactive somatostatin neuronal and non-neuronal tis- 
sues revealed that in neuronal and pancreatic tissues S-14 is the 
major end-product, whereas in mucosal tissues S-28 is the most 
abundant form [25]. This tissue-specific processing of ProSOM 
is in agreement with our present findings which demonstrated 
that S-14 is primarily produced in cells endowed with a regu- 
lated secretion mechanism whereas more of the S-28 end-prod- 
uct is observed in constitutive cells. Since PC1 and PC2 are 
primarily expressed in regulated cells [7,26], we propose (Fig. 
2) that PC2, and possibly PC1, could participate in the produc- 
tion of S-14 in regulated cells, but that in pancreatic ~-cells PC2 
would be the major S-14 convertase [24]. 
Our data also suggest that both PACE4 and furin, which are 
either widely or ubiquitously expressed, respectively [7], are the 
likely candidate S-28 convertases (Fig. 2). This result is all the 
more remarkable as the ArgLeuGluLeuGlnArglSerAla cleav- 
age site responsible for the production of S-28 contains a P6 
Arg rather than the canonical P4 Arg usually found in furin and 
PACE4 cleavage sites (see reviews [2,3]). In a previous study 
[22], we have shown that, in AtT-20 cells, the constitutive secre- 
tion of S-28 and S-14 is abolished by a mutation at the mono- 
basic Argl cleavage site preceding S-28. This suggested that the 
constitutively secreted S-14 results from the cleavage of S-28 by 
constitutive convertases, which in view of our present results 
may well be PACE4 and/or furin. The furin data presented in 
this work are also in accord with a detailed recent study de- 
monstrating a direct role of furin in the production of S-28 in 
COS-7 cells [27,28]. However, at present we cannot exclude the 
possibility that other processing enzymes not yet characterized 
at the structural level [29], could also be responsible for the 
cleavage at this monobasic site or at the monobasic Lys ~° site 
previously identified in the pro-segment of ProSOM, the cleav- 
age of which results in the production of antrin [20]. 
In conclusion, our data identified the best candidates among 
the known subtilisin/kexin-like convertases which could be re- 
sponsible for the processing of ProSOM into either S-14 or S-28 
in mammals. Our results are in good agreement with those 
observed for angler fish ProSOM-I processing, where PC2 was 
shown to effectively cleave this precursor into S-14 [29], empha- 
sizing the fact that the S-14 convertase(s) were conserved ur- 
ing evolution. 
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